Harvey Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.86M Buy
90,600
+34,260
+61% +$2.42M 1.33% 20
2025
Q4
$3.79M Sell
56,340
-1,480
-3% -$99.6K 0.81% 36
2025
Q3
$4.24M Sell
57,820
-7,000
-11% -$465K 0.9% 38
2025
Q2
$3.43M Sell
64,820
-84,355
-57% -$4.8M 0.8% 37
2025
Q1
$9.52M Sell
149,175
-36,260
-20% -$2.11M 2.49% 8
2024
Q4
$8.87M Sell
185,435
-425
-0.2% -$21.8K 2.09% 12
2024
Q3
$10.6M Sell
185,860
-180
-0.1% -$10.3K 2.66% 9
2024
Q2
$9.74M Buy
186,040
+4,550
+3% +$200K 2.56% 8
2024
Q1
$7.38M Buy
181,490
+21,380
+13% +$801K 2.16% 13
2023
Q4
$5.92M Buy
+160,110
New +$6.03M 1.96% 19
2015
Q4
Sell
-54,750
Closed -$735K 82
2015
Q3
$735K Hold
54,750
0.29% 51
2015
Q2
$1.21M Sell
54,750
-23,600
-30% -$415K 0.41% 44
2015
Q1
$1.12M Sell
78,350
-500
-0.6% -$7.21K 0.41% 44
2014
Q4
$760K Sell
78,850
-269,700
-77% -$2.4M 0.29% 51
2014
Q3
$3.17M Sell
348,550
-46,000
-12% -$438K 1.24% 25
2014
Q2
$3.9M Buy
394,550
+2,500
+0.6% +$21.2K 1.39% 25
2014
Q1
$4.98M Buy
392,050
+178,050
+83% +$2.64M 1.99% 18
2013
Q4
$3.21M Buy
214,000
+146,800
+218% +$1.89M 1.32% 24
2013
Q3
$741K Buy
+67,200
New +$560K 0.38% 40

Other funds holding HALO

Harvey Capital Management's HALO Position: Q1 2026 in Review

Harvey Capital Management increased its Halozyme (HALO) stake by 61% in Q1 2026, buying an estimated $2.42M and bringing the position to 90,600 shares worth $5.86M. The position accounts for 1.33% of the portfolio, ranked #20.

Harvey Capital Management first reported a position in HALO in Q3 2013 and has held it in 19 quarters since. The position peaked at $10.6M in Q3 2024. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Harvey Capital Management held 90,600 shares of Halozyme worth $5.86M as of Q1 2026.
  • Harvey Capital Management bought 34,260 Halozyme shares in Q1 2026, an estimated $2.42M.
  • Halozyme made up 1.33% of Harvey Capital Management's portfolio in Q1 2026, its #20 holding.
  • Harvey Capital Management first reported a position in Halozyme in Q3 2013 and has held it in 19 quarters since.
  • Harvey Capital Management's Halozyme position peaked at $10.6M in Q3 2024.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Harvey Capital Management's 13F filing for Q1 2026, filed 11 May 2026.